frontiers | Frontiers in Pharmacology

TYPE Correction
PUBLISHED 05 September 2025
DOI 10.3389/fphar.2025.1693232

Check for updates

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Steven Simoens,
steven.simoens@kuleuven.be

RECEIVED 26 August 2025
ACCEPTED 28 August 2025
PUBLISHED 05 September 2025

CITATION
Simoens S, Dodwell D, Hartevelt M, Lindgren P, Pistollato M, Pont LG, Pontes C, Roediger A, Sablek A, Van Ganse E, Wang Q, Wenger C, Wilsdon T, Xoxi E and Godman B (2025) Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.
Front. Pharmacol. 16:1693232.
doi: 10.3389/fphar.2025.1693232

COPYRIGHT
© 2025 Simoens, Dodwell, Hartevelt, Lindgren, Pistollato, Pont, Pontes, Roediger, Sablek, Van Ganse, Wang, Wenger, Wilsdon, Xoxi and Godman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies

Steven Simoens[1]*, David Dodwell[2], Michael Hartevelt[3], Peter Lindgren[4,5], Michele Pistollato[6], Lisa G. Pont[7], Caridad Pontes[8], Alexander Roediger[3], Antun Sablek[9], Eric Van Ganse[10], Qinyi Wang[11], Chris Wenger[12], Tim Wilsdon[6], Entela Xoxi[13] and Brian Godman[14,15]

[1]KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, [2]Oxford Population Health, University of Oxford, Oxford, United Kingdom, [3]Global Oncology Policy, Merck, Rahway, NJ, United States, [4]Swedish Institute for Health Economics, Lund, Sweden, [5]Health Economics, Karolinska Institute, Solna, Sweden, [6]Charles River Associates, London, United Kingdom, [7]Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia, [8]Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Barcelona, Spain, [9]Charles River Associates, Brussels, Belgium, [10]Pharmacoepidemiology Unit, Claude Bernard University Lyon 1, Lyon, France, [11]Charles River Associates, Cambridge, United Kingdom, [12]Aquantic AG, Zeiningen, Switzerland, [13]Postgraduate School of Health Economics and Management (ALTEMS), Catholic University of the Sacred Heart, Rome, Italy, [14]Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom, [15]Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

KEYWORDS

oncology combination therapies, individual patient-level healthcare data, utilization tracking, pricing and reimbursement, pharmaceutical policy, Europe, Australia

A Correction on
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies

by Simoens S, Dodwell D, Hartevelt M, Lindgren P, Pistollato M, Pont LG, Pontes C, Roediger A, Sablek A, Van Ganse E, Wang Q, Wenger C, Wilsdon T, Xoxi E and Godman B (2025). Front. Pharmacol. 16:1532022. doi: 10.3389/fphar.2025.1532022

Author Entela Xoxi was erroneously assigned to **affiliation** Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom. This affiliation has now been removed for author Entela Xoxi.

Author Lisa G. Pont was erroneously spelled as Lisa Pont.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.